NCT01705184

Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.

Phase II Study Evaluating the Interest of the Re-introduction of Pemetrexed and Platinum (Cisplatin or Carboplatin) With Prolonged Angiogenic Blocking by Bevacizumab in Non Squamous Non Small Cell Lung Cancer of Advanced Stage.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Intergroupe Francophone de Cancerologie Thoracique · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

At present, the treatment of non-squamous cell lung cancer is based on chemotherapy with platinum eventually associated with bevacizumab. A new treatment begins at progression. In colo-rectal metastatic cancer, it was demonstrated that the first-line of treatment could be administered according to a stop and go strategy respecting therapeutic breaks between sequences of identical treatment. During these therapeutic breaks, a treatment of maintenance is possibly better than an absence of treatment. These plans benefit to the patients in terms of efficiency but also in terms of toxicity, in particular neurological. The question is to know if this strategy is feasible in lung cancer.

Conditions

• Non-small Cell Lung Cancer Metastatic
• Nonsquamous Nonsmall Cell Neoplasm of Lung

Interventions

Type	Name	Description
DRUG	Cisplatin	75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence
DRUG	Bevacizumab	7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence
DRUG	Pemetrexed	500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.

Timeline

• Start date: 2012-12-01
• Primary completion: 2016-01-01
• Completion: 2017-10-01
• First posted: 2012-10-12
• Last updated: 2023-03-13

Locations

12 sites across 1 country: France